EP2155239A4 - Methods for decreasing immune response and treating immune conditions - Google Patents
Methods for decreasing immune response and treating immune conditionsInfo
- Publication number
- EP2155239A4 EP2155239A4 EP20080745187 EP08745187A EP2155239A4 EP 2155239 A4 EP2155239 A4 EP 2155239A4 EP 20080745187 EP20080745187 EP 20080745187 EP 08745187 A EP08745187 A EP 08745187A EP 2155239 A4 EP2155239 A4 EP 2155239A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- decreasing
- immune
- conditions
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/784,417 US7862812B2 (en) | 2006-05-31 | 2007-04-06 | Methods for decreasing immune response and treating immune conditions |
PCT/US2008/059511 WO2008124654A1 (en) | 2007-04-06 | 2008-04-05 | Methods for decreasing immune response and treating immune conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2155239A1 EP2155239A1 (en) | 2010-02-24 |
EP2155239A4 true EP2155239A4 (en) | 2011-05-04 |
EP2155239B1 EP2155239B1 (en) | 2015-11-18 |
Family
ID=38790477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08745187.8A Active EP2155239B1 (en) | 2007-04-06 | 2008-04-05 | Method for treating multiple sclerosis using neutralizing anti-s1p antibodies |
Country Status (7)
Country | Link |
---|---|
US (1) | US7862812B2 (en) |
EP (1) | EP2155239B1 (en) |
JP (3) | JP5885923B2 (en) |
AU (1) | AU2008237187B2 (en) |
CA (1) | CA2719055A1 (en) |
ES (1) | ES2563167T3 (en) |
WO (1) | WO2008124654A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
CA2667706A1 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
WO2009124294A2 (en) * | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
EP2445531A4 (en) * | 2009-06-24 | 2013-04-24 | Lpath Inc | Methods of increasing neuronal differentiation using antibodies to lysophoshatidic acid |
US8871920B2 (en) | 2010-04-21 | 2014-10-28 | Noxxon Pharma Ag | Lipid binding nucleic acids |
US20130259851A1 (en) * | 2010-12-01 | 2013-10-03 | Universitat Zurich | Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006078336A2 (en) * | 2004-10-28 | 2006-07-27 | Lpath Therapeutics, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
EP1731161A1 (en) * | 2000-12-22 | 2006-12-13 | Medlyte, Inc. | Compositions for the treatment of diseases associated with elevated sphingolipid concentrations |
WO2007053447A2 (en) * | 2005-10-28 | 2007-05-10 | Lpath, Inc. | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
WO2008055072A2 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
Family Cites Families (291)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30750E (en) | 1972-05-15 | 1981-09-29 | Cardiac Resuscitator Corporation | Cardiac resuscitator and monitoring apparatus |
US3953293A (en) * | 1972-05-31 | 1976-04-27 | Takeda Chemical Industries, Ltd. | Process for the preparation of xylostasin |
US3984395A (en) | 1972-07-07 | 1976-10-05 | Schering Corporation | Method of isolating gentamicin C2a |
US3974137A (en) | 1973-02-07 | 1976-08-10 | Bristol-Myers Company | Process for the preparation of 1-[L-(-)-γ-amino-α-hydroxybutyryl]-kanamycin A (RD-1341A) |
US3959255A (en) | 1973-05-10 | 1976-05-25 | Roussel-Uclaf | Antibiotic aminoglycosides, and process of preparation |
FR2232326B1 (en) | 1973-06-05 | 1977-11-10 | Pfizer | |
JPS5644076B2 (en) | 1973-07-12 | 1981-10-16 | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3962429A (en) | 1973-08-01 | 1976-06-08 | Chugai Seiyaku Kabushiki Kaisha | Method for reducing side effects of aminoglycoside antibiotics and composition therefor |
US3953422A (en) * | 1973-08-17 | 1976-04-27 | Smithkline Corporation | Deoxyglucose derivatives |
JPS554118B2 (en) * | 1973-08-29 | 1980-01-29 | ||
US4170642A (en) | 1973-10-01 | 1979-10-09 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Derivatives of kanamycin A |
US3988316A (en) | 1973-12-19 | 1976-10-26 | Schering Corporation | Antibiotics sisomicin and verdamicin I and complex containing same |
US4011390A (en) * | 1974-02-15 | 1977-03-08 | Schering-Plough Corporation | Semi-synthetic aminocyclitol aminoglycoside antibiotics and methods for the preparation thereof |
FR2263745B1 (en) | 1974-03-12 | 1977-12-02 | Roussel Uclaf | |
FR2263747B1 (en) | 1974-03-12 | 1977-12-02 | Roussel Uclaf | |
CA1046512A (en) | 1974-03-19 | 1979-01-16 | Peter J.L. Daniels | Derivatives of diaminocyclitols and method for their preparation |
CH630644A5 (en) * | 1974-04-10 | 1982-06-30 | Takeda Chemical Industries Ltd | METHOD FOR PRODUCING DESOXYAMINOGLYCOSIDE ANTIBIOTICS. |
US4125707A (en) | 1974-05-28 | 1978-11-14 | Societa' Farmaceutici Italia S.P.A. | Protected pseudotrisaccharide intermediate for paromomycin and neomycin derivatives |
US4049498A (en) | 1974-06-05 | 1977-09-20 | Schering Corporation | Methods for the preparation of semi-synthetic aminocyclitol aminoglycoside antibiotics |
US4217446A (en) | 1974-10-26 | 1980-08-12 | Pfizer Inc. | ωAmino-2-hydroxyalkyl derivatives of aminoglycoside antibiotics |
US4051315A (en) | 1974-11-13 | 1977-09-27 | Bristol-Myers Company | 6"-Deoxykanamycin B and 6"-deoxytobramycin |
FR2290908A1 (en) | 1974-11-13 | 1976-06-11 | Roussel Uclaf | NEW AMINOGLYCOSIDIC DERIVATIVE AND ITS SALTS, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
US4012576A (en) * | 1974-12-12 | 1977-03-15 | Bristol-Myers Company | Antibiotic complex Bu 2183 |
US3978214A (en) | 1975-05-02 | 1976-08-31 | Schering Corporation | Novel 4,6-di-o-(aminoglycosyl)-2-deoxystreptamine, method for its manufacture, method for its use as an antiprotozoal agent and compositions useful thereof |
US3997524A (en) | 1975-05-02 | 1976-12-14 | Schering Corporation | Process for the manufacture of 6'-N-alkyl derivatives of sisomicin and verdamicin; novel intermediates useful therein, and novel 6'-N-alkylverdamicins prepared thereby |
US4044123A (en) | 1975-05-02 | 1977-08-23 | Schering Corporation | 6'-N-alkyl-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, methods for their use as antibacterial agents and compositions useful therefor |
US4009328A (en) * | 1975-05-02 | 1977-02-22 | Schering Corporation | Aminoglycoside 66-40C, method for its manufacture, method for its use as an intermediate in the preparation of known antibiotics and novel antibacterials |
US3984393A (en) | 1975-09-08 | 1976-10-05 | The Upjohn Company | Aminoglycoside antibiotics |
US4038478A (en) | 1975-09-08 | 1977-07-26 | The Upjohn Company | O-glycoside ortho esters of neamine containing compounds |
US3996205A (en) | 1975-09-08 | 1976-12-07 | The Upjohn Company | Aminoglycoside antibiotics and intermediates |
US4002608A (en) * | 1975-11-04 | 1977-01-11 | Schering Corporation | 1-N-alkyl-aminoglycoside-XK-88 derivatives and methods for their manufacture |
JPS5265250A (en) | 1975-11-24 | 1977-05-30 | Bristol Myers Co | Whole synthesizing process for antimicrobial agents |
US4003922A (en) * | 1975-11-24 | 1977-01-18 | Bristol-Myers Company | Synthesis of cis-1,4-cyclohexadiene dioxide |
US4195170A (en) * | 1975-12-09 | 1980-03-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | 3',4'-Episulfido kanamycin B compounds |
GB1529243A (en) | 1976-02-25 | 1978-10-18 | Pfizer Ltd | Process for the preparation of aminoglycoside derivatives and cyclic urethane intermediates for use therein |
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
ES459606A1 (en) | 1976-06-10 | 1978-12-16 | Canas Rodriguez Antonio | Synthetic aminoglycosides |
JPS52153942A (en) | 1976-06-16 | 1977-12-21 | Microbial Chem Res Found | Preparation of kanamicin c deoxy derivatives and kanamicine c or its deoxy derivatives |
NZ184213A (en) | 1976-06-16 | 1980-05-27 | Pfizer | 2-deoxystreptamine aminoglycosides and antibacterial pharmaceutical compositions |
US4136254A (en) * | 1976-06-17 | 1979-01-23 | Schering Corporation | Process of selectively blocking amino functions in aminoglycosides using transition metal salts and intermediates used thereby |
US4230847A (en) | 1976-06-17 | 1980-10-28 | Schering Corporation | Aminoglycoside antibiotic compounds |
US4283528A (en) | 1976-06-17 | 1981-08-11 | Schering Corporation | 1-N-aminohydroxyacyl derivatives of gentamicin B |
US4085208A (en) * | 1976-06-21 | 1978-04-18 | Schering Corporation | Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor |
US4066752A (en) * | 1976-06-21 | 1978-01-03 | Schering Corporation | 1-Desamino-1-hydroxy and 1-desamino-1-epi-hydroxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols; 1-desamino-1-oxo-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, intermediates and use as antibacterial agents |
US4032404A (en) | 1976-07-14 | 1977-06-28 | Bristol-Myers Company | Fermentation process for producing apramycin and nebramycin factor V' |
US4146617A (en) * | 1976-07-15 | 1979-03-27 | Roussel Uclaf | Desoxystreptamine derivatives, salts, pharmaceutical compositions and method of use |
US4187372A (en) * | 1976-09-08 | 1980-02-05 | Abbott Laboratories | Seldomycin factor 5 derivative |
US4189569A (en) * | 1976-09-08 | 1980-02-19 | Abbott Laboratories | Seldomycin factor 5 derivatives |
JPS5356661A (en) | 1976-10-28 | 1978-05-23 | Shionogi & Co Ltd | Novel amino glycoside antibiotics derivatives |
US4170643A (en) | 1977-04-13 | 1979-10-09 | Labaz | Aminoglycoside-aminocyclitol derivatives and method of use |
US4347354A (en) | 1977-04-28 | 1982-08-31 | Bristol-Myers Company | Preparation of 1-N-[ω-amino-α-hydroxyalkanoyl]aminoglycoside polysilylated antibiotics and products obtained therefrom |
US4424343A (en) * | 1977-04-28 | 1984-01-03 | Bristol Myers Company | Preparation of 1-N- ω-amino-α-hydroxyalkanoyl!kanamycin polysilylates and products |
US4140849A (en) * | 1977-05-23 | 1979-02-20 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Kanamycin C derivatives |
US4212859A (en) | 1977-06-24 | 1980-07-15 | Schering Corporation | 2'-Hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, method for their use as antibacterial agents, and compositions useful therefor |
DK308878A (en) | 1977-08-18 | 1979-02-19 | Pfizer | AMINOGLYOSIDE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION |
CA1105455A (en) * | 1977-09-19 | 1981-07-21 | Junji Irisawa | Aminoglycoside derivatives |
JPS5461151A (en) * | 1977-10-25 | 1979-05-17 | Shionogi & Co Ltd | Novel aminoglycoside derivative |
US4176178A (en) | 1977-12-21 | 1979-11-27 | Abbott Laboratories | 2-Deoxy-2'-N-acyl and alkyl fortimicins A and B |
US4196197A (en) * | 1977-12-21 | 1980-04-01 | Abbott Laboratories | 2'N-Acyl and alkyl-6'-N-alkyl- and 6',6'-di-N-alkyl derivatives of fortimicins A and B |
US4214076A (en) | 1977-12-21 | 1980-07-22 | Abbott Laboratories | 2'-N-Substituted fortimicin B and derivatives |
US4192867A (en) * | 1977-12-21 | 1980-03-11 | Abbott Laboratories | 2-Deoxyfortimicin A, 4-N-alkyl and 4-N-acyl-2-deoxyfortimicin B derivatives |
US4319022A (en) * | 1977-12-21 | 1982-03-09 | Abbott Laboratories | 2-O-Substituted sulfonyl derivatives of fortimicin B |
US4214075A (en) | 1977-12-21 | 1980-07-22 | Abbott Laboratories | 6'-Epi-fortimicin A and B derivatives |
US4207314A (en) | 1977-12-21 | 1980-06-10 | Abbott Laboratories | Isofortimicin |
US4187296A (en) * | 1977-12-21 | 1980-02-05 | Abbott Laboratories | 2-N-acyl and alkyl 6-epi-fortimicin B and derivatives |
US4187298A (en) * | 1977-12-21 | 1980-02-05 | Abbott Laboratories | 2'N-acyl and alkyl fortimicin B and derivatives, 4,2'-N,N'diacyl and dialkyl fortimicin B derivatives 4-N-acyl-2'-N-alkyl and 4-N-alkyl-2'-N-acyl fortimicin B derivatives |
US4317904A (en) * | 1977-12-21 | 1982-03-02 | Abbott Laboratories | 1,2-Epiminofortimicin B |
US4187297A (en) * | 1977-12-21 | 1980-02-05 | Abbott Laboratories | 3-De-O-methyl-2-N-acyl and alkyl fortimicins A and B |
US4187299A (en) * | 1977-12-21 | 1980-02-05 | Abbott Laboratories | Fortimicin E |
US4205070A (en) | 1977-12-21 | 1980-05-27 | Abbott Laboratories | 6'N-Alkyl- and 6',6'-di-N-alkyl derivatives of fortimicins A and B |
US4183920A (en) * | 1977-12-21 | 1980-01-15 | Abbott Laboratories | 4-N-Acyl, 2'-N-acyl and 4,2'-N,N'-diacylfortimicin E derivatives |
US4169198A (en) | 1977-12-21 | 1979-09-25 | Abbott Laboratories | 2-Deoxyfortimicin B |
JPS5492951A (en) | 1977-12-29 | 1979-07-23 | Shionogi & Co Ltd | Novel aminoglycoside derivative |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
JPS6030320B2 (en) | 1978-01-13 | 1985-07-16 | 山之内製薬株式会社 | New antibiotics and their production methods |
US4223022A (en) | 1978-01-16 | 1980-09-16 | Schering Corporation | Stabilized aminoglycoside antibiotic formulations |
US4226978A (en) | 1978-03-13 | 1980-10-07 | Miles Laboratories, Inc. | β-Galactosyl-umbelliferone-labeled aminoglycoside antibiotics and intermediates in their preparation |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4181797A (en) * | 1978-07-10 | 1980-01-01 | Bristol-Myers Company | 1-N-(ω-amino-α-hydroxyalkanoyl) derivatives of 4'-deoxy-6'-N-methylkanamycin A |
FR2435481A1 (en) | 1978-09-06 | 1980-04-04 | Roussel Uclaf | NOVEL AMINOGLYCOSIDES DERIVED FROM DESOXYSTREPTAMINE AND SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND APPLICATION AS MEDICAMENTS |
JPS5538345A (en) * | 1978-09-11 | 1980-03-17 | Shionogi & Co Ltd | Novel aminoglycoside derivative |
JPS5540621A (en) | 1978-09-14 | 1980-03-22 | Shionogi & Co Ltd | Novel aminoglycoside derivative |
SE447386B (en) * | 1978-10-18 | 1986-11-10 | Kowa Co | AMINOGLYCOSIDES, COMPOSITION CONTAINING THEM, AND PROCEDURE FOR PREPARING THEM |
IE48972B1 (en) | 1978-11-11 | 1985-06-26 | Microbial Chem Res Found | The production of a selectively protected n-acylated derivative of an aminoglycosidic antibiotic |
HU179145B (en) * | 1979-02-01 | 1982-08-28 | Chinoin Gyogyszer Es Vegyeszet | Process for microbiological producing sysomycin with fermenting micromonospora danubiensis |
US4207415A (en) | 1979-02-05 | 1980-06-10 | Abbott Laboratories | Method of producing 2-deoxyfortimicin A |
US4208407A (en) | 1979-02-05 | 1980-06-17 | Abbott Laboratories | 5-Deoxyfortimicin A, 2,5-dideoxyfortimicin A and the corresponding 4-N-acyl and alkyl fortimicin B derivatives thereof and intermediates therefor |
HU179146B (en) | 1979-02-06 | 1982-08-28 | Chinoin Gyogyszer Es Vegyeszet | Process for microbiological producing sysnycin with fermenting micromonospora rosea |
US4223024A (en) | 1979-03-12 | 1980-09-16 | Abbott Laboratories | 4"-O-Alkylgentamicins and sagamicins |
US4219642A (en) | 1979-03-29 | 1980-08-26 | Abbott Laboratories | Fortimicin AO |
US4216210A (en) | 1979-03-29 | 1980-08-05 | Abbott Laboratories | Fortimicins AM and AP derivatives |
US4214078A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | Fortimicin AL |
US4214079A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | 4-N, 2'-N and 4,2'-Di-N-fortimicin AL derivatives |
US4213974A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | 4-N,2'-N and 4,2'-Di-N-fortimicin AO derivatives |
US4219643A (en) | 1979-03-29 | 1980-08-26 | Abbott Laboratories | Fortimicin AN |
US4213972A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | 4-N, 2'-N and 4,2'Di-N-fortimicins AH and AI |
US4213971A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | 4-N, 2'-N and 4,2'-Di-N-fortimicin AD derivatives |
US4220756A (en) | 1979-03-29 | 1980-09-02 | Abbott Laboratories | Method of producing 3-O-demethylfortimicin B,4-N-alkylfortimicin B derivatives and related aminoglycoside antibiotics |
US4219644A (en) | 1979-03-29 | 1980-08-26 | Abbott Laboratories | Fortimicins AH and AI |
US4214080A (en) | 1979-03-29 | 1980-07-22 | Abbott Laboratories | Fortimicins AM and AP |
US4330673A (en) | 1979-03-29 | 1982-05-18 | Abbott Laboratories | Process for producing 3-O-demethylaminoglycoside and novel 3-O-demethylfortimicin derivatives |
JPS5629598A (en) | 1979-08-18 | 1981-03-24 | Toyo Jozo Co Ltd | Novel amino sugar antibiotic g-367-2 and its preparation |
US4297486A (en) | 1979-04-04 | 1981-10-27 | Toyo Jozo Kabushiki Kaisha | Aminoglycoside antibiotic G-367-1 and method for the production thereof |
DE2921974A1 (en) | 1979-05-30 | 1980-12-11 | Bayer Ag | SELECTIVELY PROTECTED 1-N- (OMEGA-AMINOALKYLOXYCARBONYL) -SISOMICIN DERIVATIVES |
DE2921973A1 (en) * | 1979-05-30 | 1980-12-11 | Bayer Ag | SISOMICIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
US4250170A (en) * | 1979-06-11 | 1981-02-10 | Bristol-Myers Company | Antibacterial agents Bu-2349A and B and method of using same |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4251516A (en) * | 1979-09-26 | 1981-02-17 | Abbott Laboratories | 2-Deoxy-3-O-Demethylfortimicins |
US4250304A (en) * | 1979-09-26 | 1981-02-10 | Abbott Laboratories | 2-Deoxy-2-substituted fortimicin A and B and derivatives |
US4252972A (en) * | 1979-09-26 | 1981-02-24 | Abbott Laboratories | Fortimicin B-1,2:4,5-bis-carbamates |
US4251511A (en) * | 1979-10-02 | 1981-02-17 | The Upjohn Company | Antibiotic and fermentation process of preparing |
US4288547A (en) | 1979-11-13 | 1981-09-08 | Haruo Yamamoto | Fermentative process for preparing antibiotics of the gentamicin class |
US4387219A (en) | 1979-11-13 | 1983-06-07 | Sterling Drug Inc. | 2-Hydroxy gentamicin compounds |
DE3000841A1 (en) * | 1980-01-11 | 1981-07-16 | Bayer Ag, 5090 Leverkusen | INSULATION AND CLEANING OF AMINOGLYCOSIDE ANTIBIOTIAKA |
JPS56118097A (en) | 1980-02-25 | 1981-09-16 | Microbial Chem Res Found | Kanamycin a derivative and its preparation |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4468512A (en) | 1980-09-22 | 1984-08-28 | Eli Lilly And Company | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides |
US4468513A (en) | 1980-09-22 | 1984-08-28 | Eli Lilly And Company | 2'-N-Acylated and 2'-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides |
US4424345A (en) * | 1980-09-22 | 1984-01-03 | Eli Lilly And Company | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process |
US4424344A (en) * | 1980-09-22 | 1984-01-03 | Eli Lilly And Company | 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process |
DE3101376A1 (en) * | 1981-01-17 | 1982-09-02 | Bayer Ag, 5090 Leverkusen | SISOMICIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
DE3206725A1 (en) | 1981-05-13 | 1982-12-02 | Merck Patent Gmbh, 6100 Darmstadt | PERSONALLY SOLUBLE SALTS OF AMINOGLYCOSIDANTIBIOTICS |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS5815994A (en) | 1981-07-22 | 1983-01-29 | Microbial Chem Res Found | Kanamycin derivative modified at 2' position and its preparation |
JPS5821692A (en) * | 1981-07-29 | 1983-02-08 | Microbial Chem Res Found | Novel aminoglycoside |
FI822671L (en) * | 1981-08-07 | 1983-02-08 | Sandoz Ag | AMINOGLYCOSIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION FOR FRAMSTAELLNING AV DEM, PHARMACEUTICAL COMPOSITION INNEHAOLLANDE DEM |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4418193A (en) | 1982-04-09 | 1983-11-29 | Abbott Laboratories | Method of producing 2-epi-fortimicin A |
JPS58213774A (en) | 1982-06-04 | 1983-12-12 | Kowa Co | Novel aminoglycoside |
US4645760A (en) * | 1982-07-30 | 1987-02-24 | Health Research Inc. | Activated aminoglycosides and aminoglycoside-aminocyclitols pharmaceutical compositions and method of use |
US4493831A (en) * | 1982-10-25 | 1985-01-15 | Fujisawa Pharmaceutical Co., Ltd. | Aminoglycoside derivatives |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
AU575038B2 (en) | 1983-01-28 | 1988-07-21 | Fujisawa Pharmaceutical Co., Ltd. | Aminoglycoside derivatives, eg 2'n-palmitoyl-kasugamycin |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6042394A (en) * | 1983-08-18 | 1985-03-06 | Kowa Co | Novel aminoglycoside and its preparation |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4626513A (en) | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
ATE56096T1 (en) | 1984-03-15 | 1990-09-15 | Immunex Corp | TEST FOR INSTANT DETECTION OF LIGANDS, TEST KIT AND ITS PREPARATION. |
US4658830A (en) * | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
SE455445B (en) | 1984-08-28 | 1988-07-11 | Pharmacia Ab | ANTIBODIES AGAINST SIALOSYL LACTOTETRAUS (IV? 723NEUACLCOSE? 714) AND THE ANTIBODY'S RESPONSE ANTIGEN'S USE IN TUMOR DIAGNOSTICS |
EP0173648A3 (en) | 1984-08-30 | 1988-04-27 | Ciba-Geigy Ag | New monoclonal antibodies to glycoconjugates, processes for their production, and applications |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4656160A (en) * | 1984-11-29 | 1987-04-07 | Fujisawa Pharmaceutical Co., Ltd. | Aminoglycoside derivatives |
US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US4737456A (en) * | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
JPS6253997A (en) | 1985-09-03 | 1987-03-09 | Kowa Co | Novel amino glycoside and pharmaceutical preparation containing same |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IT1200774B (en) * | 1985-10-10 | 1989-01-27 | Pierrel Spa | AMIKACINA FEELING PROCEDURE |
US5008288A (en) * | 1986-01-06 | 1991-04-16 | Alfred Stracher | Carnitine directed pharmaceutical agents |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
JPH0764866B2 (en) | 1987-02-24 | 1995-07-12 | 財団法人微生物化学研究会 | 1-N- (4-amino-3-fluoro-2-hydroxybutyryl) kanamycin |
DE3883899T3 (en) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | CHANGED ANTIBODIES. |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
IT1225484B (en) | 1987-11-27 | 1990-11-14 | Pierrel Spa | SYNTHESIS PROCEDURE OF AMIKACINA |
DE3741056A1 (en) * | 1987-12-04 | 1989-08-24 | Behringwerke Ag | MANUMYCINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5030723A (en) | 1988-05-31 | 1991-07-09 | The Biomembrane Institute | Long-chain glycolipid structure |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5442047A (en) | 1991-12-04 | 1995-08-15 | Schering Corporation | Process for preparing isepamicin |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
IT1237490B (en) * | 1989-09-22 | 1993-06-07 | Chementecno S R L Monza Milano | PROCEDURE FOR THE SYNTHESIS OF 1 N (S DELTA AMINO ALFA IDROSSIBUTIRRIL) KAMANYCIN A BASED ON THE TREATMENT OF 1 N (S DELTA BENZYOXYCARBONLAMINE ALPHA HYDROXYBUTYRRIL) 3.6 'OF N BENZYLSYCARBONYLKANAMYCIN A WITH FORMIC ACID |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ATE111917T1 (en) * | 1990-03-08 | 1994-10-15 | Opos Biochimica Srl | METHODS OF PRODUCTION OF AMIKACIN PRECURSORS. |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
US5248824A (en) | 1990-12-31 | 1993-09-28 | The Biomembrane Institute | Method of preparing N,N,N-trimethylsphingosine |
US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
US5677288A (en) | 1991-05-15 | 1997-10-14 | Cypros Pharmaceutical Corporation | Use of aminoglycosides to protect against excitotoxic neuron damage |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
US5430160A (en) | 1991-09-23 | 1995-07-04 | Florida State University | Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides |
US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
ATE244763T1 (en) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5260288A (en) * | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
US5369030A (en) | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5488038A (en) * | 1992-11-27 | 1996-01-30 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria |
US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
WO1994016731A1 (en) | 1993-01-22 | 1994-08-04 | Sloan-Kettering Institute For Cancer Research | Ganglioside-klh conjugate vaccines with qs-21 |
CN1040177C (en) | 1993-04-23 | 1998-10-14 | 江苏省微生物研究所 | 1-N-ethyl gentamicin derivative and its preparing method |
US5444087A (en) | 1993-10-19 | 1995-08-22 | Bristol-Myers Squibb Company | Manumycin compounds |
US5929039A (en) | 1993-11-15 | 1999-07-27 | Baker Medical Research Institute | Method for treating cardiac dysfunction and pharmaceutical compositions useful therefor |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
DK0742789T3 (en) | 1994-02-02 | 2000-11-13 | Liposome Co Inc | Pharmaceutically active compounds and liposomes and methods for their use |
US5593853A (en) * | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
US5585476A (en) | 1994-02-15 | 1996-12-17 | Maclennan; Alexander J. | Molecular cloning and expression of G-protein coupled receptors |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5627171A (en) | 1994-04-11 | 1997-05-06 | Oncomembrane, Inc. | Sphingosine-1-phosphate/trimethylsphingosine composition |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US6046037A (en) * | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
US5677189A (en) | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
US5916911A (en) * | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US6031071A (en) * | 1996-01-24 | 2000-02-29 | Biophage, Inc. | Methods of generating novel peptides |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5830916A (en) | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
DE19621038A1 (en) | 1996-05-24 | 1997-11-27 | Boehringer Ingelheim Kg | Aminoguanidines, processes for their preparation and medicaments containing these compounds |
DE19636255C1 (en) | 1996-09-06 | 1997-10-23 | Fresenius Medical Care De Gmbh | High availability dialysis unit with automatic removal of accumulated lime-scale deposits |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
US6140060A (en) | 1996-12-12 | 2000-10-31 | Chun; Jerold J. M. | Cloned lysophosphatidic acid receptors |
US5919687A (en) | 1996-12-24 | 1999-07-06 | John Hopkins University | Recombinant N-SMases and nucleic acids encoding same |
US6310191B1 (en) | 1998-02-02 | 2001-10-30 | Cosmix Molecular Biologicals Gmbh | Generation of diversity in combinatorial libraries |
US5912144A (en) | 1997-04-24 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Edg-1-receptor homolog |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
US6210976B1 (en) * | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
US5989803A (en) | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
US6423527B1 (en) | 1997-09-29 | 2002-07-23 | Children's Hospital Medical Center Of Northern California | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
JP4460155B2 (en) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | Humanization of mouse antibodies |
US6057126A (en) | 1997-12-24 | 2000-05-02 | Allelix Biopharmaceuticals, Inc. | Mammalian EDG-5 receptor homologs |
US6098631A (en) | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
JP2002501751A (en) * | 1998-01-29 | 2002-01-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | New compound |
AU765809B2 (en) | 1998-02-12 | 2003-10-02 | Emory University | Sphingolipid derivatives and their methods of use |
JP2002508940A (en) | 1998-03-13 | 2002-03-26 | デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド | Humanized antibodies and uses thereof |
US6130067A (en) | 1998-05-20 | 2000-10-10 | Smithkline Beecham Corporation | Human EDG3sb gene |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
WO2000000207A1 (en) * | 1998-06-29 | 2000-01-06 | Children's Hospital Of Los Angeles | Treatment of hyperproliferative disorders |
JP2002531466A (en) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス, インコーポレイテッド | Humanized antibodies to gamma interferon |
JP2000293181A (en) | 1999-04-12 | 2000-10-20 | Daiichikosho Co Ltd | Karaoke singing equipment having features in lyrics picture extracting function |
WO2001037836A1 (en) | 1999-11-24 | 2001-05-31 | Emory University | Diimino-piperazine derivatives for use as modulators of cell regulation |
US6306911B1 (en) | 2000-02-07 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as neutral sphingomyelinase inhibitors |
JP2001261575A (en) | 2000-03-13 | 2001-09-26 | General Hospital Corp | Method for regulating vasoconstriction and its composition |
US6571638B2 (en) | 2000-06-30 | 2003-06-03 | Sawtek, Inc. | Surface-acoustic-wave pressure sensor and associated methods |
WO2002017899A2 (en) | 2000-08-31 | 2002-03-07 | University Of Connecticut | Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
US20030125533A1 (en) | 2000-10-06 | 2003-07-03 | Sophia Kossida | Regulation of human sphingosine kinase-like protein |
EP1363643A2 (en) * | 2000-12-22 | 2003-11-26 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
US20020150582A1 (en) | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
US7674580B2 (en) | 2002-01-17 | 2010-03-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
DE60324416D1 (en) | 2002-05-16 | 2008-12-11 | Novartis Ag | USE OF EDG RECEPTOR BINDING AGENTS FOR CANCER THERAPY |
WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
JP2008541760A (en) * | 2005-05-31 | 2008-11-27 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | Regulation of T cell recruitment |
US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
-
2007
- 2007-04-06 US US11/784,417 patent/US7862812B2/en not_active Expired - Fee Related
-
2008
- 2008-04-05 ES ES08745187.8T patent/ES2563167T3/en active Active
- 2008-04-05 EP EP08745187.8A patent/EP2155239B1/en active Active
- 2008-04-05 CA CA2719055A patent/CA2719055A1/en not_active Abandoned
- 2008-04-05 WO PCT/US2008/059511 patent/WO2008124654A1/en active Application Filing
- 2008-04-05 JP JP2010502342A patent/JP5885923B2/en not_active Expired - Fee Related
- 2008-04-05 AU AU2008237187A patent/AU2008237187B2/en not_active Ceased
-
2014
- 2014-10-27 JP JP2014218711A patent/JP2015042662A/en active Pending
-
2016
- 2016-02-15 JP JP2016025452A patent/JP2016155814A/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1731161A1 (en) * | 2000-12-22 | 2006-12-13 | Medlyte, Inc. | Compositions for the treatment of diseases associated with elevated sphingolipid concentrations |
WO2006078336A2 (en) * | 2004-10-28 | 2006-07-27 | Lpath Therapeutics, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
WO2007053447A2 (en) * | 2005-10-28 | 2007-05-10 | Lpath, Inc. | Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
WO2008055072A2 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
Non-Patent Citations (4)
Title |
---|
SCHWAB SUSAN R ET AL: "Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.", SCIENCE (NEW YORK, N.Y.) 9 SEP 2005 LNKD- PUBMED:16151014, vol. 309, no. 5741, 9 September 2005 (2005-09-09), pages 1735 - 1739, XP002629304, ISSN: 1095-9203 * |
See also references of WO2008124654A1 * |
VISENTIN BARBARA ET AL: "Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages", CANCER CELL, CELL PRESS, US, vol. 9, no. 3, 1 March 2006 (2006-03-01), pages 225 - 238, XP002455666, ISSN: 1535-6108, DOI: 10.1016/J.CCR.2006.02.023 * |
ZOU WEIPING: "Immunosuppressive networks in the tumour environment and their therapeutic relevance.", NATURE REVIEWS. CANCER APR 2005 LNKD- PUBMED:15776005, vol. 5, no. 4, April 2005 (2005-04-01), pages 263 - 274, XP002629303, ISSN: 1474-175X * |
Also Published As
Publication number | Publication date |
---|---|
JP2010523597A (en) | 2010-07-15 |
AU2008237187B2 (en) | 2013-12-05 |
US20070280933A1 (en) | 2007-12-06 |
JP2015042662A (en) | 2015-03-05 |
ES2563167T3 (en) | 2016-03-11 |
WO2008124654A1 (en) | 2008-10-16 |
CA2719055A1 (en) | 2008-10-16 |
US7862812B2 (en) | 2011-01-04 |
JP5885923B2 (en) | 2016-03-16 |
EP2155239B1 (en) | 2015-11-18 |
AU2008237187A1 (en) | 2008-10-16 |
JP2016155814A (en) | 2016-09-01 |
EP2155239A1 (en) | 2010-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190214T1 (en) | Compositions and methods for treating purpura | |
IL200265A0 (en) | Endo-surgical device and method | |
MY147458A (en) | Interocclusal appliance and method | |
EP2322672A4 (en) | Heating device and heating method | |
IL208496A0 (en) | Bioretention system and method | |
EP2227293A4 (en) | Magnaretractor system and method | |
EP2121511A4 (en) | Micropackaging method and devices | |
EP2308884A4 (en) | Method for producing -hetero-substituted alkylhalohydrosilane and use thereof | |
IL197781A0 (en) | Lyophilization methods and apparatuses | |
HK1162366A1 (en) | Devices and methods for treating and or preventing diseases | |
GB0810413D0 (en) | Method and system | |
GB0807018D0 (en) | Antibodies and treatment | |
GB0813687D0 (en) | Article and associated method | |
HK1212698A1 (en) | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them | |
IL232271A0 (en) | Yahreit system and method | |
EP2323579A4 (en) | Methods and devices for treating presbyopia | |
EP2155239A4 (en) | Methods for decreasing immune response and treating immune conditions | |
ZA200906243B (en) | Endo-surgical device and method | |
GB0718684D0 (en) | Treatment method | |
EP2276036A4 (en) | Basket and ph adjusting device | |
GB0717518D0 (en) | Process and device | |
GB0707069D0 (en) | Methods and uses | |
TWI318091B (en) | Trace-adjusting system and method | |
TWI319298B (en) | Via-adjusting method and system | |
EP2205396A4 (en) | Method and grinding appliance for grinding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091105 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110404 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20110325BHEP Ipc: A61K 39/00 20060101AFI20081028BHEP Ipc: C07K 16/18 20060101ALI20110325BHEP Ipc: C07K 16/30 20060101ALI20110325BHEP |
|
17Q | First examination report despatched |
Effective date: 20120207 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LPATH, INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150605 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 761175 Country of ref document: AT Kind code of ref document: T Effective date: 20151215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008041260 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2563167 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160311 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160218 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 761175 Country of ref document: AT Kind code of ref document: T Effective date: 20151118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160218 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160318 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160318 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160219 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008041260 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20160819 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20160722 Year of fee payment: 9 Ref country code: IT Payment date: 20160725 Year of fee payment: 9 Ref country code: GB Payment date: 20160721 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20160721 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160405 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20160721 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160405 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008041260 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170405 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20171229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171103 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170405 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080405 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160430 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20180703 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151118 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170406 |